Introduction {#s1}
============

Glucosinolates (GLSs) are amino acid-derived specialized metabolites found in the Brassicales order including vegetables like cabbage, oil crops like canola and mustards as well as the model plant *Arabidopsis thaliana* ([@B16]). GLSs are hydrolyzed by myrosinase enzymes to form biologically active compounds such as isothiocyanates, nitriles, oxazolidine-2-thiones, and various indole derivatives. The hydrolysis products are deterrent or toxic to herbivores and pests, which makes GLSs play an important role in the native plant defense. From a human perspective, GLSs are flavor compounds, health-promoting agents, and biopesticides. A recent literature survey found 88 GLS structures that have been well characterized, 49 less well characterized and in some cases of uncertain existence, and many more candidates suggested and awaiting characterization ([@B4]). In discussions of biosynthesis, it is meaningful to classify GLSs according to precursor amino acid. GLSs derived from five aliphatic standard amino acids (alanine, valine, leucine, isoleucine, and methionine) are well established. In addition, three aromatic amino acids serve as precursors for GLSs: tryptophan for indole GLSs, and phenylalanine and tyrosine for benzenic GLSs. All GLSs share a common core structure with a thioglucose moiety and a sulfated oxime. Diversity of GLSs is due to the variation of precursor amino acid, chain elongation of precursor amino acids, secondary modifications of amino acid side chain, and decoration on the glucose moiety. GLSs derived from chain-elongated amino acids are only known with certainty in the case of methionine, phenylalanine, and isoleucine ([@B4]), but GLSs from once and twice chain elongated leucine have also been tentatively verified from nature.

The biosynthetic pathway of glucosinolates has three phases consisting of a side chain elongation, a core structure pathway and secondary modifications ([@B46]). For simplicity, the "core structure pathway" is shortened to the "core pathway" in the rest of this paper. The chain elongation pathway includes the enzymes BCAT4, MAM1-3, IPMI, and IPMDH1 ([@B46]). The core pathway is comprised of seven enzymatic steps. The substrate-specific cytochrome P450s of the CYP79 family constitute the entry point, catalyzing the conversion of amino acids to the corresponding oximes. Subsequently, downstream enzymes of the core pathway convert the oximes successively. While some enzymes in the core pathway are shared by all GLSs, other steps include several gene products with more limited substrate specificity or regulation. It is generally believed that some *A. thaliana* enzymes are mainly responsible for biosynthesis from aliphatic amino acids (mainly homologs of methionine), while others are mainly responsible for biosynthesis from tryptophan or possibly all aromatic amino acids ([@B46]). However, relatively little is still known of the exact enzymology of the individual core pathway enzymes. In *A. thaliana*, the downstream enzymes GGP1 and SUR1 are believed to be shared for all amino acid precursors. Generally, conversion of tryptophan or possibly all aromatic amino acids to GLSs is believed to additionally depend on CYP83B1, GSTF9, UGT74B1, and SOT16, and conversion of homo-methionine and possibly all aliphatic amino acids to GLSs is believed to depend on CYP83A1, GSTF11, UGT74C1, and SOT18 ([@B46]). For simplicity, we refer to these generally agreed groupings as the "aromatic" and "aliphatic" core pathways in the following, although our results suggest that these designations may be overly simplified.

Much is known about the enzymes that control the entry to GLS biosynthesis. In *A. thaliana*, CYP79A2 catalyzes conversion of phenylalanine to phenylacetaldoxime in the biosynthesis of benzyl GLS (BGLS), at least upon overexpression, while the role *in planta* remains poorly understood ([@B54]). CYP79B2 and CYP79B3 catalyze conversion of tryptophan to indole-3-acetaldoxime for indole GLS biosynthesis ([@B34]; [@B57]). CYP79F1 converts mono- to hexahomomethionine to the corresponding oximes for the biosynthesis of short- and long-chain methionine-derived GLSs whereas CYP79F2 exclusively accepts the long-chain homologs pentahomo- and hexahomomethionine ([@B8]). However, the function of two additional *A. thaliana* enzymes, CYP79C1 and CYP79C2, remained unknown, although based on sequence similarity to other CYP79s they were anticipated to control entry to GLS biosynthesis.

Expression levels of *CYP79C1* and *CYP79C2* have been investigated by several authors using transcriptomics analysis in *A. thaliana*. Under normal growth conditions, 14 days after germination, *CYP79C1* and *CYP79C2* were not expressed ([@B7]; [@B39]). Generally, the expression levels of *CYP79C1* and *CYP79C2* are below the detection limit level in vegetative parts (root, leaf, stem) at all developmental stages ([@B25]). However, *CYP79C1* is expressed in floral organs (e.g. ovules, flowers, and seeds) (Col-0 accession) and *CYP79C2* is expressed in embryo central cells (Landsberg *erecta* accession) ([@B48]; [@B25]).

In this study, we identified catalytic functions of CYP79C1 and CYP79C2 from *A. thaliana* by *Agrobacterium*-mediated transient expression in *Nicotiana benthamiana*. Each CYP79 enzyme was expressed together with the downstream enzymes of the aromatic and aliphatic core pathways as well as the enzymes of the chain elongation pathway, followed by analysis of GLS profiles. The CYP79Cs primarily resulted in GLSs derived from leucine and phenylalanine when the chain elongation pathway was absent, but excluded phenylalanine and included homologs of methionine and leucine when the chain elongation pathway was present. Differential effects of the "aliphatic" and "aromatic" core pathways were observed. Engineering the GLS biosynthetic pathways in *N. benthamiana* is a novel, untargeted approach to characterize CYP79 enzymes.

Materials and Methods {#s2}
=====================

Generation and Transformation of Constructs {#s2_1}
-------------------------------------------

All constructs were cloned from the vector pCAMBIA330035Su by USER cloning ([@B40]; [@B14]). The NEB^®^ DH10B strain (New England Biolabs, \#C3019H) was used to assemble and amplify the constructs. The gene sequences of CYP79D2 (NC_035172.1), CYP79F1 (AT1G16410), CYP83A1 (AT4G13770), CYP83B1 (AT4G31500), and GGP1 (AT4G30530) were amplified with in-house templates. The gene sequences of CYP79C1 (AT1G79370) and CYP79C2 (AT1G58260) were amplified from gBlocks from IDT (Integrated DNA Technologies Inc, USA). All genes were inserted into the vector pCAMBIA330035Su flanked with 35S promoter and 35S terminator. Constructs C11 containing the genes *GSTF11* and *GGP1*, and C10 containing the genes *SUR1*, *UGT74C1*, and *SOT18* were previously published ([@B35]). The construct with *APK2* gene was published by [@B31]. The construct ORF2 harboring the genes *SUR1*, *UGT74B1*, and *SOT16* and the construct ORF1-GGP1 harboring the genes *CYP79A2*, *CYP83B1*, and *GGP1* were described in ([@B15]). The chain elongation pathway constructs BCAT4 (AT3G19710), BAT5 (AT4G12030), MAM1 (AT5G23010), IPMI-LSU1 (AT4G13430), IPMI-SSU3 (AT3G58990), and IPMDH1 (AT5G14200) were from the previous study ([@B11]). The primers used in this study are summarized in [**Supplementary Table S1**](#SM2){ref-type="supplementary-material"}.

All constructs were separately transformed into *Agrobacterium tumefaciens* strain pGV3850 by electroporation (2 mm cuvette, 2.5 kV, 400 Ω, and 25 μF) in a Bio-Rad GenePulser (Bio-Rad, Hercules, CA, USA). Cells were incubated at 28°C for 2 h after 200 µl LB media was added. The cultures were plated on LB agar plates containing 30 μg/ml rifampicin and 50 μg/ml kanamycin and incubated at 28°C for 3 days. Colony PCR was used to confirm the presence of the constructs in the strain.

Transient Expression in *N. benthamiana* {#s2_2}
----------------------------------------

*Agrobacterium tumefaciens* strains harboring the different constructs were grown in YEP media containing 30 μg/ml rifampicin and 50 μg/ml kanamycin at 28°C and 220 rpm overnight. Cells were harvested by centrifugation at 4000 × *g* for 10 min at room temperature. Subsequently, the pellets were resuspended in infiltration buffer (10 mM MES, 10 mM MgCl~2~, pH 5.6) with 100 μM acetosyringone (3,5-dimethoxy-4-hydroxyacetophenone, Sigma-Aldrich, Steinheim, Germany) and slightly shaken at room temperature for 1--3 h. OD~600~ for each culture was measured and infiltration buffer was added to adjust to OD~600~ = 0.2. Equal volumes of each infiltration buffer containing individual construct were mixed according to the combination design. For expression of the core pathway, the proper amount of infiltration buffer was added for the combinations with fewer than six constructs, resulting in each individual construct with OD~600~ ≈ 0.03. For expression of the chain elongation pathway and the core pathway, the proper amount of infiltration buffer was added for the combinations with fewer than 12 constructs, resulting in each individual construct with OD~600~ ≈ 0.017. The silencing suppressor p19 ([@B51]) was included in all experiments. Leaves of *N. benthamiana* plants (around 4 weeks old, four to six leaves stage) were infiltrated using the mixed cultures of the different combinations.

Plant Extraction and GLS Analysis {#s2_3}
---------------------------------

Four leaf disks of 1 cm diameter were harvested from each infiltrated leaf and weighed 5 days after infiltration. Metabolites were extracted from the leaf disks using 85% aq. methanol. The resulting extract was diluted 5.0 fold with water and the diluted samples were directly analyzed by LC-MS/qTOF for identification of native GLSs. For quantification, GLSs were analyzed as desulfo-GLSs (dsGLSs) after enzymatic on-column desulfation as previously described ([@B22]; [@B10]). Allyl GLS (K^+^ salt, PhytoLab, Vestenbergsgreuth, Germany) was added as internal standard before desulfation with a final concentration of 1 µM. Subsequently, the extract was loaded onto DEAE-Sephadex columns to bind GLSs. Columns were washed twice with 70% methanol and twice with water. After sulfatase treatment overnight, dsGLSs were eluted with water.

GLS Analysis by Desulfation and LC-MS/Triple Quadrupole {#s2_4}
-------------------------------------------------------

GLSs were analyzed as dsGLSs after enzymatic desulfation as previously described ([@B22]; [@B10]) with modifications for separation of leucine and isoleucine-derived dsGLSs. Briefly, chromatography was performed on an Advance UHPLC system (Bruker, Bremen, Germany). Separation was achieved on a Kinetex 1.7u XB-C18 column (100 x 2.1 mm, 1.7 µm, 100 Å, Phenomenex, Torrance, CA, USA). Formic acid (0.05%) in water and acetonitrile (supplied with 0.05% formic acid) were employed as mobile phases A and B, respectively. An extended elution profile was used: 0--0.5 min, 2% B; 0.5--3.2 min, 2--30% B; 3.2--4.0 min 30--100% B, 4.0--4.5 min 100% B, 4.5--4.6 min, 100--2% B, and 4.6--6.0 min 2% B. The mobile phase flow rate was 400 µl min^−1^. The column temperature was maintained at 40°C. The liquid chromatography was coupled to an EVOQ Elite TripleQuad mass spectrometer (Bruker, Bremen, Germany) equipped with an electrospray ion source (ESI) operated in positive ionization mode. The instrument parameters were optimized by infusion experiments with pure standards. The ion spray voltage was maintained at +3500 V. Cone temperature was set to 350°C and cone gas to 20 psi. Heated probe temperature was set to 400°C and probe gas flow to 40 psi. Nebulizing gas was set to 60 psi and collision gas to 1.6 mTorr. Nitrogen was used as probe and nebulizing gas and argon as collision gas. Active exhaust was constantly on. Multiple reaction monitoring (MRM) was used to monitor analyte precursor ion to product ion transitions: MRM transitions for phenylalanine-, tryptophan, and tyrosine-derived ds-GLSs and ds-GLS derived from chain-elongated methionine were chosen as previously reported ([@B10]; [@B42]) and from LC-MS/qTOF data for valine-, leucine-, and isoleucine-derived ds-GLSs as well as ds-GLS derived from chain-elongated leucine. Details on transitions and collision energies are described in [**Supplementary Table S2**](#SM2){ref-type="supplementary-material"}. Both Q1 and Q3 quadrupoles were maintained at unit resolution. Bruker MS Workstation software (Version 8.2.1, Bruker, Bremen, Germany) was used for data acquisition and processing. Allyl GLS was used as internal standard for quantification as previously described ([@B22]). Authentic references of ds1ME, ds1MP, and ds2MP were obtained as previously reported ([@B41]). The response factors representing the relationship between the internal standard allyl GLS and 1ME, 1MP, and 2MP were set to 1 as amounts of the pure references were insufficient for accurate determination of mass by weighing.

Confirmation of GLS Identity by LC-MS of Intact as Well as Desulfo-GLSs {#s2_5}
-----------------------------------------------------------------------

The quantification of GLSs after desulfation is specific for each isomeric side chain structure, but does not provide a critical test of the correct position of the sulfate group in the native metabolites. Hence, intact GLS analysis was additionally performed. In general, where authentic references were available, correct positioning of the sulfate group as well as the general metabolite identity was confirmed by LC-MS/Q-TOF analysis (**Supplementary Methods** and [**Supplementary Figures S2--S8**](#SM1){ref-type="supplementary-material"}). However, in one positive control with very high levels of 1ME, peak broadening suggested additional accumulation of an isomer. Minor levels of this isomer were also observed in experiments with CYP79C1. Since peak broadening was not observed for authentic intact 1ME or desulfated GLSs ([**Supplementary Figure S8**](#SM1){ref-type="supplementary-material"}), we suggest that the peak broadening was due to heterogeneity of sulfation, possibly due to an endogenous sulfotransferase in tobacco. However, both isomers obviously reflected biosynthesis of the ds-GLS core structure, so the heterogeneity was not a problem for the characterization of the CYP79C enzymes. We isolated authentic 1ME as described ([@B1]) ([**Supplementary Figure S1**](#SM1){ref-type="supplementary-material"}). For 1MP and 2MP, for which authentic references of intact GLSs were not available, the retention times ([**Supplementary Figure S2** and **S5**](#SM1){ref-type="supplementary-material"}) and fragmentations (results not shown) were as expected for GLSs, suggesting that these were likewise correctly sulfated. Identities of all reported GLSs were subsequently confirmed by comparison of retention time, accurate mass, and fragmentation patterns from MS2 experiments, including distinction of the isomers 1MP and 2MP with different retention times as dsGLSs and GLSs ([**Supplementary Table S2**](#SM2){ref-type="supplementary-material"}).

Results {#s3}
=======

GLS Production by Co-Expression of *CYP79C1* and *CYP79C2* With the Aliphatic Core Pathway {#s3_1}
------------------------------------------------------------------------------------------

To investigate which GLSs are produced by CYP79C1 and CYP79C2, and thereby the substrate specificity of the two enzymes, we first co-expressed *CYP79C1* and *CYP79C2* with the remaining genes of the aliphatic core pathway in *N. benthamiana* ([**Figure 2A**](#f2){ref-type="fig"}). In addition, the APS kinase gene *APK2* from *Arabidopsis* was co-expressed alongside the core pathway genes as it has been shown to be critical for efficient regeneration of the co-factor PAPS (3\'-phospho-adenosine-5\'-phosphosulfate) in the final sulfotransferase step that converts dsGLS into intact GLS ([@B31]). The chemical structures and amino acid precursors of all the GLSs detected in this study are shown in [**Figure 1**](#f1){ref-type="fig"}. Co-expression with *CYP79C2* resulted in high accumulation of leucine-derived 2MP (35 nmol/g fw) and phenylalanine-derived BGLS (76 nmol/g fw) as well as low levels of isoleucine-derived 1MP (1.2 nmol/g fw) and tryptophan-derived I3M (0.16 nmol/g fw) ([**Figure 2B**](#f2){ref-type="fig"} and [**Supplementary Table S3**](#SM2){ref-type="supplementary-material"}). When *CYP79C1* was co-expressed, accumulation of 2MP, 1MP and BGLS was observed ([**Figure 2C**](#f2){ref-type="fig"}). The overall levels of the three GLSs were much lower, with the highest level being BGLS at 2.0 nmol/g fw ([**Supplementary Table S3**](#SM2){ref-type="supplementary-material"}). Additionally, a tiny amount of valine-derived 1ME was observed with *CYP79C1* ([**Figure 2C**](#f2){ref-type="fig"}). Co-expression of *CYP79D2* (a cyanogenic CYP from *Manihot esculenta*) together with the aliphatic core pathway, was included as positive control and resulted in valine-derived 1ME and isoleucine-derived 1MP ([**Figure 2D**](#f2){ref-type="fig"}), which is consistent with a previous report ([@B33]). Additionally, leucine-derived 2MP was detected at very low levels ([**Figure 2D**](#f2){ref-type="fig"}), suggesting that CYP79D2 has a low degree of acceptance of leucine as a substrate. A small but statistically significant amount of BGLS (0.76 nmol/g) was detected from the core pathway without any CYP79 enzyme added ([**Figure 2E**](#f2){ref-type="fig"} and [**Supplementary Table S3**](#SM2){ref-type="supplementary-material"}), suggesting that an endogenous enzyme, possibly of the CYP79 family, from *N. benthamiana* is able to produce the phenylacetaldoxime that is further converted by the core pathway. Interestingly, this background level of BGLS was not observed with CYP79D2, maybe due to some degree of substrate competition. Hence, background levels from control experiments were not subtracted from reported levels from experiments with inserted CYP79 genes. The high level of the aromatic BGLS that accumulated upon co-expression of CYP79C2 with the "aliphatic" core pathway was unexpected, suggesting that the enzymes in the core pathway are less side chain specific than hitherto believed.

![The chemical structures and amino acid precursors of all the glucosinolates (GLSs) detected in this study. Side-chain structures of 3MB and 4MP were deduced from *m*/*z* value and a biochemical argument (known chain elongation of Leu, not Ile, by the chain elongation enzymes used).](fpls-11-00057-g001){#f1}

![Glucosinolates (GLSs) accumulated in *Nicotiana benthamiana* upon transient expression of *CYP79C1* and *CYP79C2* in combination with the aliphatic core pathway. **(A)** Scheme of introduced enzymes including different CYP79 enzymes (pink) and remaining "aliphatic" core pathway enzymes as well as the stimulating enzyme APK2 (green). The combination without CYP79 represents the negative control and the combination with CYP79D2 is the positive control. **(B)** GLSs accumulated with construct including CYP79C2. **(C)** GLSs accumulated with constructs including CYP79C1. **(D)** GLSs accumulated with constructs including CYP79D2. **(E)** GLSs accumulated with the negative control constructs without CYP79 co-expressed. Data of each box plot represent nine biological replicates in nanomole per gram fresh weight. n.d. represents not detected. Data in **(B--E)** are box-and-whisker representations indicating the 10th (lower whisker), 25th (base of box), 75th (top of box), and 90th (top whisker) percentilies. The line within the box is the median and outliers are not shown. Exact values are listed in [**Supplementary Table S3**](#SM2){ref-type="supplementary-material"}. *P-*values (two-sided Student\'s *t*-test) used to compare the same type of GLS yields among B, C, and E are listed in [**Supplementary Table S4**](#SM2){ref-type="supplementary-material"}.](fpls-11-00057-g002){#f2}

GLS Production by Co-Expression of *CYP79C1* and *CYP79C2* With the Aromatic Core Pathway {#s3_2}
-----------------------------------------------------------------------------------------

Next, we co-expressed *CYP79C1* and *CYP79C2* together with the genes of the aromatic core pathway in *N. benthamiana* ([**Figure 3A**](#f3){ref-type="fig"}). The gene *GSTF9* was not co-expressed in this experiment since an endogenous activity in *N. benthamiana* was known to efficiently catalyze this step ([@B15]). In the experiments with *CYP79C2*, the observed GLS profile was very similar to the one observed from co-expression with the aliphatic core pathway, except that levels were generally higher and that minute amount of the tyrosine-derived pOHB was also detected ([**Figure 3B**](#f3){ref-type="fig"}). More 2MP (180 nmol/g fw) and BGLS (169 nmol/g fw) were produced than 1MP (3.5 nmol/g fw), pOHB (0.97 nmol/g fw), and I3M (0.24 nmol/g fw) from co-expression of *CYP79C2* ([**Supplementary Table S5**](#SM2){ref-type="supplementary-material"}). Noticeably, the level of the aliphatic 2MP derived from leucine was much higher using the aromatic core pathway than the aliphatic core pathway ([**Supplementary Tables S3**](#SM2){ref-type="supplementary-material"} and [**S5**](#SM2){ref-type="supplementary-material"}). This supports the finding above that the enzymes in core pathways are less side chain specific than hitherto believed. Co-expression of *CYP79C1* produced a GLS profile similar to the profile obtained with the aliphatic core pathway, i.e. 2MP, 1MP, and BGLS, with the exception that 1ME was not produced ([**Figure 3C**](#f3){ref-type="fig"}). The positive control for engineering the aromatic core pathway, CYP79A2, produced BGLS (480 nmol/g fw) and tiny amounts of pOHB (0.77 nmol/g fw) ([**Supplementary Table S5**](#SM2){ref-type="supplementary-material"} and [**Figure 3D**](#f3){ref-type="fig"}). This result was in agreement with the previous conclusion that phenylalanine is the main substrate of CYP79A2 ([@B54]), but extended the known substrate profile to include tyrosine when presented by a physiological mix of the various amino acids. The lack of observed pOHB by previous authors is apparently due to the much increased sensitivity of the analytical instrumentation used here. Finally, small amounts of 2MP and BGLS were observed from the negative control, i.e. the core pathway without CYP79 enzymes ([**Figure 3E**](#f3){ref-type="fig"}). This result suggests that an endogenous enzyme, possibly of the CYP79 family, can produce the corresponding oximes, to be converted by the remaining enzymes of the aromatic core pathway to 2MP and BGLS. The background level of 2MP was not observed in the positive control with co-expression of CYP79A2, which is in agreement with a similar observation in the experiments with the aliphatic core pathway.

![Glucosinolates (GLSs) accumulated in *Nicotiana benthamiana* upon transient expression of *CYP79C1* and *CYP79C2* in combination with the aromatic core pathway. **(A)** Scheme of introduced enzymes including different CYP79 enzymes (pink) and remaining "aromatic" core pathway enzymes as well as the stimulating enzyme APK2 (green). The combination without CYP79 represents the negative control and the combination with CYP79A2 is the positive control. **(B)** GLSs accumulated with constructs including CYP79C2. **(C)** GLSs accumulated with constructs including CYP79C1. **(D)** GLSs accumulated with constructs including CYP79A2. **(E)** GLSs accumulated with the negative control constructs without CYP79 co-expressed. Data of each box plot represent nine biological replicates in nanomole per gram fresh weight. n.d. represents not detected. Data in **(B--E)** are box-and-whisker representations indicating the 10th (lower whisker), 25th (base of box), 75th (top of box), and 90th (top whisker) percentiles. The line within the box is the median and outliers are not shown. Exact values are listed in [**Supplementary Table S5**](#SM2){ref-type="supplementary-material"}. *P-*values (two-sided Student\'s *t*-test) used to compare the same type of GLS yields among B, C, and E are listed in [**Supplementary Table S6**](#SM2){ref-type="supplementary-material"}.](fpls-11-00057-g003){#f3}

CYP79C1 and CYP79C2 Also Metabolize Chain-Elongated Amino Acids {#s3_3}
---------------------------------------------------------------

To investigate whether also chain-elongated amino acids are metabolized by CYP79C1 and CYP79C2, we co-expressed *CYP79C1* and *CYP79C2* with the remaining enzymes of the aliphatic core pathway and the chain elongation pathway in *N. benthamiana* ([**Figure 4A**](#f4){ref-type="fig"}). The chain elongation pathway has been reported to elongate the side chain of methionine in 1--3 cycles, leucine in 1--2 cycles and phenylalanine in one cycle, resulting in production of homomethionine, dihomomethionine, trihomomethionine, homoleucine, dihomoleucine, and homophenylalanine in *Escherichia coli* ([@B43]). As chain elongation of isoleucine was not detected with this specific set of chain elongation genes, we deduced that produced alkyl GLS could only be the isomers expected from leucine, i.e. with one branching methyl group at the "ω minus 1"-position (either homoleucine-derived 3-methylbutyl GLS, 3MB, or dihomoleucine-derived 4-methylpentyl GLS, 4MP) ([**Figure 1**](#f1){ref-type="fig"}). Furthermore, we included co-expression of the bile acid transporter 5 gene (*BAT5*), as BAT5 facilitates transport of chain-elongated compounds between chloroplast and the cytosol ([@B11]). We found that co-expression of *CYP79C2* at these conditions resulted in low levels of 3MB at 2.1 nmol/g fw and 4MP at 0.45 nmol/g fw ([**Figure 4B**](#f4){ref-type="fig"} and [**Supplementary Table S7**](#SM2){ref-type="supplementary-material"}), indicating that CYP79C2 accepts homoleucine and dihomoleucine as substrates. Moreover, trace levels of dihomomethionine-derived 4-(methylthio)butyl GLS (4MTB) and 4-(methylsulfinyl)butyl GLS (4MSB) were detected ([**Figure 4B**](#f4){ref-type="fig"}), but only in a few biological replicates ([**Supplementary Table S7**](#SM2){ref-type="supplementary-material"}), suggesting that CYP79C2 may occasionally accept dihomomethionine as substrate. Interestingly, 2MP and 1MP derived from non-chain-elongated amino acids accumulated, but the levels were much lower than those detected from CYP79C2 without the chain elongation pathway ([**Supplementary Tables S3**](#SM2){ref-type="supplementary-material"}, [**S5**](#SM2){ref-type="supplementary-material"} and [**S7**](#SM2){ref-type="supplementary-material"}). On the contrary, BGLS (also from non-chain-elongated phenylalanine) was not detected at all in these experiments. These results suggest that the *in vivo* activity of CYP79C2 depends on the presence or absence of the chain-elongation machinery. Co-expression of *CYP79C1* resulted in 4MP at 1.8 nmol/g fw and 4MTB at 3.7 nmol/g fw, suggesting that the substrate specificity of CYP79C1 includes dihomoleucine and dihomomethionine ([**Figure 4C**](#f4){ref-type="fig"} and [**Supplementary Table S7**](#SM2){ref-type="supplementary-material"}). For CYP79C1, the effect of co-expression with the chain elongation pathway was even more pronounced, as no GLSs derived from non-chain-elongated amino acids were detected ([**Figure 4C**](#f4){ref-type="fig"}). The positive control to validate the function of the entire pathway, CYP79F1, showed high accumulation of 51 nmol/g fw 3MB, 100 nmol/g fw 4MP, and 33 nmol/g fw 4MTB, as well as low level of 9.6 nmol/g fw 3-(methylthio)propyl GLS (3MTP) and 1.7 nmol/g fw 4MSB ([**Figure 4D**](#f4){ref-type="fig"} and [**Supplementary Table S7**](#SM2){ref-type="supplementary-material"}). Trace amounts of trihomomethionine-derived 5-(methylsulfinyl)-pentyl GLS (5MSP) were detected (data not shown). This demonstrates that CYP79F1 catalyzed the conversion of homoleucine, dihomoleucine, homomethionine, dihomomethionine, and trihomomethionine to the corresponding oximes, as previously shown ([@B35]; [@B43]).

![Glucosinolates (GLSs) accumulated in *Nicotiana benthamiana* upon transient expression of *CYP79C1* and *CYP79C2* in combination with the chain elongation and aliphatic core pathways. **(A)** Scheme of introduced enzymes including the chain elongation pathway enzymes (green), different CYP79 enzymes (pink), and the remaining "aliphatic" core pathway enzymes as well as the stimulating enzyme APK2. The combination with CYP79F1 is the positive control. **(B)** GLSs accumulated with constructs including CYP79C2. **(C)** GLSs accumulated with constructs including CYP79C1. **(D)** GLSs accumulated with constructs including CYP79F1. Data of each box plot represent 12 biological replicates in nanomole per gram fresh weight. n.d. represents not detected. The aromatic GLSs BGLS, pOHB, and I3M were not detected in any of these experiments, and are hence not indicated in the graphs. Data in **(B--D)** are box-and-whisker representations indicating the 10th (lower whisker), 25th (base of box), 75th (top of box), and 90th (top whisker) percentiles. The line within the box is the median and outliers are not shown. Exact values are listed in [**Supplementary Table S7**](#SM2){ref-type="supplementary-material"}. *P-*values (two-sided Student\'s *t*-test) used to compare the same type of GLS yields between B and C are listed in [**Supplementary Table S8**](#SM2){ref-type="supplementary-material"}.](fpls-11-00057-g004){#f4}

Discussion {#s4}
==========

In this study, we characterized the substrate specificity of CYP79C1 and CYP79C2 by transiently co-expressing the genes together with the GLS biosynthetic pathways in *N. benthamiana*. From subsequent analysis of GLS profile, we deduced the substrate use of the tested CYP79s. Unexpectedly, it turned out that the resulting GLS profile depended strongly on the co-expressed pathway, either the "aromatic" or the "aliphatic" core pathway with or without the chain elongation pathway in addition.

In the absence of the chain elongation pathway, we found that CYP79C1 and CYP79C2 both channeled aliphatic leucine and isoleucine and aromatic phenylalanine into the corresponding GLS. For CYP79C2, leucine and phenylalanine were major and isoleucine was a minor substrate, independent of core pathway. For CYP79C1, the preferred substrate depended on the core pathway: aromatic phenylalanine was the sole major substrate with the "aliphatic" core pathway, while aliphatic leucine was the sole major substrate with the "aromatic" core pathway. In most cases, various minor substrates were also used. However, when the aliphatic core pathway was supplemented with the chain elongation pathway, neither of the two CYP79Cs used phenylalanine as precursor at all. Other differences were also observed: CYP79C2 showed substrate specificity to homo- and dihomoleucine, while CYP79C1 stopped metabolizing non-chain-elongated amino acids and apparently exclusively channeled dihomoleucine and dihomomethionine into GLS biosynthesis ([**Figures 2**](#f2){ref-type="fig"}--[**4**](#f4){ref-type="fig"}, [@B3]). A possible explanation for why the CYP79C specificities depended so strongly on the co-expressed biosynthetic pathways could be competition for available substrates. Although direct protein-protein interactions between CYP79s and the chain elongation machinery are unlikely, due to different subcellular localization ([@B46]), the variation may reflect the ability to obtain physical proximity between the CYP79s and the remaining core pathway enzymes in the heterologous tobacco host ([@B3]).

Our work describes a novel approach to investigate substrate specificities of CYP79 enzymes as compared to previous genetic and *in vitro* biochemical characterization ([@B55]). For our two controls CYP79D2 and CYP79A2, our approach confirmed previous results, but also showed slightly expanded substrate specificities resulting in very minor additional GLS products (leucine accepted by CYP79D2 and tyrosine accepted by CYP79A2).

Interestingly, the anticipated outcome *a priori* of using either aliphatic or aromatic core pathways was not reflected in the results. Rather, both pathways were efficient in forming aromatic BGLS as well as aliphatic 2MP from CYP79C2, with even higher levels of 2MP being produced by the aromatic core pathway. Evidently, the distinction between aliphatic and aromatic core pathways---that is based on co-expression analysis ([@B55]; [@B46]) of transcriptomics data from *A. thaliana*---is an oversimplification reflecting observations in the native host where many other factors including regulatory mechanisms may play a major role in controlling the biosynthetic machinery of glucosinolate formation and thus the observable glucosinolate profile. Apparently, the enzymes in the core pathways have substrate specificities toward both aliphatic and aromatic substrates when expressed in a heterologous host.

The main detected GLS products resulting from the two characterized CYP79C1 and CYP79C2 (BGLS, 1ME, 1MP, 2MP, 3MB, and 4MP) are not generally detected in *A. thaliana* Col-0 ([@B6]). Minor peaks tentatively identified by HPLC-UV as 1ME and 2MP have been detected in seeds of a few *A. thaliana* accessions, always at very low levels, and not from leaves of any accession ([@B26]). Neither was any corresponding hydrolysis product reported from 19 A*. thaliana* accessions ([@B18]). Two chain-elongated leucine-derived (3MB and 4MP) were claimed from unspecified *A. thaliana* accessions but precise experimental data were not presented ([@B45]). BGLS has repeatedly been referred to as present sporadically and at extremely low levels in *A. thaliana* ([@B53]), but without presentation of actual data. In conclusion, BGLS, 1ME, 1MP, 2MP, 3MB, and 4MP have never been conclusively reported from any accession of *A. thaliana*. For this reason, the ability of CYP79C1 and CYP79C2 to channel phenylalanine, leucine and homologs (and to some degree valine and isoleucine) into GLS biosynthesis, is surprising. The specific expression in floral and embryonal tissues could suggest either a specific defensive function in these tissues or a role in non-defensive biochemistry.

Within the CYP79C subfamily, only CYP79C1 and CYP79C2 in *A. thaliana* have been annotated. The amino acid sequence of CYP79C1 shares 51.65% similarity with CYP79C2, although members in a subfamily have normally 55% amino acid sequence identity ([@B37]). However, a slightly lower similarity is not uncommon since the rule is arbitrary and the decision to classify an enzyme into a subfamily depends on how it clusters within a phylogenetic tree and not strictly on the sequence similarity ([@B37]). Furthermore, many reported RNA sequences share high percentage of identity (\>70%) with the coding sequences of CYP79C1 and CYP79C2. These include many species from the Brassicaceae family and Cleomaceae family, both GLS-producing families in the Brassicales order.

The classification into P450 families and subfamilies is based on amino acid sequence and thus it is common to see enzymes with similar substrate specificity cluster in different subfamilies. This is apparent by CYP79C1 and CYP79C2 showing rather broad substrate specificities including both aliphatic and aromatic amino acids, which resembles what is observed for some of the CYP79Ds ([**Table 1**](#T1){ref-type="table"}) ([@B19]; [@B20]; [@B29]). Typically, the reported substrate specificity for CYP79s is toward single or related amino acids, and hence either toward aliphatic or aromatic amino acids. For instance, members of the CYP79B subfamily (e.g. CYP79B1, CYP79B2, and CYP79B3), channel tryptophan into GLS biosynthesis ([**Table 1**](#T1){ref-type="table"}) ([@B34]; [@B57]; [@B36]). Similarly, CYP79E1 and CYP79E2 accept tyrosine ([**Table 1**](#T1){ref-type="table"}) ([@B38]). Likewise, the enzymes from CYP79A subfamily (CYP79A1, CYP79A2, CYP79A61) are reported to accept tyrosine, phenylalanine, or tryptophan, except for CYP79A118 that takes all three aromatic amino acids ([**Table 1**](#T1){ref-type="table"}) ([@B17]; [@B54]; [@B21]; [@B30]). The characterized members of the CYP79F subfamily has specificity toward chain-elongated methionine derivatives ([**Table 1**](#T1){ref-type="table"}) ([@B8]), except for CYP79F6 that has been proposed to metabolize homophenylalanine ([@B28]).

###### 

The substrate specificity and affinity of the CYP79 family members.

  ----------------------------------------------------------------------------------------------------------------------------------
  CYP79 enzyme             Substrate specificity   Substrate affinity (K~M~)     Plant species             Locus        Reference
  ------------------------ ----------------------- ----------------------------- ------------------------- ------------ ------------
  CYP79A1                  Tyrosine                K~M,~ ~=~ 220 µM              *Sorghum bicolor*         LOC8061413   [@B17]

  CYP79A2                  Phenylalanine           K~M,~ ~=~ 6.7 µM              *Arabidopsis thaliana*    AT5G05260    [@B54]

  CYP79A8                  Leucine                 Not tested                    *Hordeum vulgare*         ACJ70085     [@B27]

  CYP79A12                 Leucine                 Not tested                    *Hordeum vulgare*         ACM24114     [@B27]

  CYP79A61                 Phenylalanine,\         K~M,~ ~Phe~ = 117.2 μM,\      *Zea mays*                AKJ87843     [@B21]
                           Tryptophan              K~M,~ ~Trp~ = 150.2 µM                                               

  CYP79A118\               Tyrosine,\              K~M,~ ~Tyr~ = 456 µM,\        *Taxus baccata*           ART92261     [@B30]
  (N-terminal truncated)   Phenylalanine,\         K~M,~ ~Phe~ = 21690 μM,\                                             
                           Tryptophan              K~M,~ ~Trp~ = 24150 μM                                               

  CYP79B1                  Tryptophan              K~M,~ ~=~ 29 µM               *Sinapis alba*            AAD03415     [@B36]

  CYP79B2                  Tryptophan              K~M,~ ~=~ 21 µM               *Arabidopsis thaliana*    AT4G39950    [@B34]

  CYP79B3                  Tryptophan              Not tested                    *Arabidopsis thaliana*    AT2G22330    [@B57]

  CYP79C1                  Valine,\                Not tested\                   *Arabidopsis thaliana*    AT1G79370    This study
                           Phenylalanine,\         Not tested\                                                          
                           Leucine,\               Not tested\                                                          
                           Isoleucine              Not tested                                                           

  CYP79C2                  Phenylalanine,\         Not tested\                   *Arabidopsis thaliana*    AT1G58260    This study
                           Leucine,\               Not tested\                                                          
                           Isoleucine,\            Not tested\                                                          
                           Tryptophan,\            Not tested\                                                          
                           Tyrosine                Not tested                                                           

  CYP79D1                  Valine,\                K~M,~ ~Val~ = 2200 µM,\       *Manihot esculenta*       AAV97889     [@B2]
                           Isoleucine              K~M,~ ~Ile~ = 1300 µM                                                

  CYP79D2                  Valine,\                Not tested\                   *Manihot esculenta*       AAV97888     [@B33]
                           Isoleucine              Not tested                                                           

  CYP79D3                  Valine,\                Not tested\                   *Lotus japonicus*         AAT11920     [@B13]
                           Isoleucine              Not tested                                                           

  CYP79D4                  Valine,\                Not tested\                   *Lotus japonicus*         AAT11921     [@B13]
                           Isoleucine              Not tested                                                           

  CYP79D6v3                Phenylalanine,\         K~M,~ ~Phe~ = 744 μM,\        *Populus trichocarpa*     AHF20912     [@B19]
                           Leucine,\               K~M,~ ~Leu~ = 447 μM,\                                               
                           Isoleucine,\            K~M,~ ~Ile~ = 526 µM,\                                               
                           Tryptophan,\            K~M,~ ~Trp~ = 1427 μM,\                                              
                           Tyrosine                K~M,~ ~Tyr~ = 1828 µM                                                

  CYP79D6v4                Phenylalanine,\         Not tested\                   *Populus nigra*           AHI88992     [@B20]
                           Leucine,\               Not tested\                                                          
                           Isoleucine,\            Not tested\                                                          
                           Tryptophan,\            Not tested\                                                          
                           Tyrosine                Not tested                                                           

  CYP79D7v2                Phenylalanine,\         K~M,~ ~Phe~ = 2901 μM,\       *Populus trichocarpa*     AHF20913     [@B19]
                           Leucine,\               K~M,~ ~Leu~ = 633 μM,\                                               
                           Isoleucine,\            K~M,~ ~Ile~ = 851 µM,\                                               
                           Tryptophan              K~M,~ ~Trp~ = 285 μM                                                 

  CYP79D60                 Phenylalanine,\         K~M,~ ~Phe~ = 580 μM,\        *Erythroxylum fischeri*   AOW44273     [@B29]
                           Isoleucine,\            K~M,~ ~Ile~ = 1280 μM,\                                              
                           Leucine,\               K~M,~ ~Leu~ = 230 μM,\                                               
                           Tryptophan,\            K~M,~ ~Trp~ = 2740 μM,\                                              
                           Tyrosine                K~M,~ ~Tyr~ = 6090 μM,                                               

  CYP79D61                 Phenylalanine,\         Not tested\                   *Erythroxylum fischeri*   AOW44271     [@B29]
                           Isoleucine,\            Not tested\                                                          
                           Leucine,\               Not tested\                                                          
                           Tryptophan,\            Not tested\                                                          
                           Tyrosine                Not tested                                                           

  CYP79D62                 Phenylalanine,\         K~M,~ ~Phe~ = 670 μM,\        *Erythroxylum coca*       AOW44274     [@B29]
                           Isoleucine,\            K~M,~ ~Ile~ = 3270 μM,\                                              
                           Leucine,\               K~M,~ ~Leu~ = 590 μM,\                                               
                           Tryptophan,\            K~M,~ ~Trp~ = 1090 μM,\                                              
                           Tyrosine                K~M,~ ~Tyr~ = 4990 μM,                                               

  CYP79D63                 Tryptophan              K~M,~ ~=~ 480 µM              *Erythroxylum coca*       AOW4427      [@B29]

  CYP79E1                  Tyrosine                Not tested                    *Triglochin maritima*     AF140609_1   [@B38]

  CYP79E2                  Tyrosine                Not tested                    *Triglochin maritima*     AF140610_1   [@B38]

  CYP79F1                  1homoMet,\              Not tested\                   *Arabidopsis thaliana*    AT1G16410    [@B8]
                           2homoMet,\              K~M,~ ~2homoMet~ = 34 µM,\                                           
                           3homoMet,\              K~M,~ ~3homoMet~ = 37 µM,\                                           
                           4homoMet,\              K~M,~ ~4homoMet~ = 194 µM,\                                          
                           5homoMet,\              K~M,~ ~5homoMet~ = 216 µM,\                                          
                           6homoMet,               K~M,~ ~6homoMet~ = 74 µM                                             

  CYP79F2                  5homoMet,\              K~M,~ ~5homoMet~ = 374 µM,\   *Arabidopsis thaliana*    AT1G16400    [@B8]
                           6homoMet,               K~M,~ ~6homoMet~ = 26 µM                                             
  ----------------------------------------------------------------------------------------------------------------------------------

1homoMet, homomethionine; 2homoMet, dihomomethionine; 3homoMet, trihomomethionine; 4homoMet, tetrahomomethionine; 5homoMet, pentahomomethionine; 6homoMet, hexahomomethionine.

Noticeably, CYP79F1 has affinity toward chain-elongated leucine derivatives when expressed in heterologous hosts such as *N. benthamiana* ([@B35]), which is beyond its endogenous enzymatic activity in wild type *A. thaliana*. A possible explanation to why some CYP79s exhibit an apparent different substrate specificity in heterologous hosts could be substrate availability or lack of co-factors such as e.g. chaperones ([@B12]). This raises the question of physiologically relevant substrate specificity versus promiscuity. The term enzyme promiscuity describes enzyme activities other than those for which an enzyme evolved and that are not part of the organism\'s physiology ([@B24]). In summary, despite our present characterization of CYP79C1 and CYP79C2 in a heterologous host, further research is needed to reveal the biological role of CYP79C1 and CYP79C2 in *A. thaliana*.

Oximes are not only the intermediates in the biosynthesis of GLSs, but also involved in the biosynthesis of other defense compounds like cyanogenic glucosides, non-cyanogenic hydroxynitriles, and rhodiocyanosides ([@B32]; [@B2]; [@B38]; [@B54]; [@B13]; [@B47]). Additionally, oximes are direct defense compounds, for example, in poplar ([@B19]; [@B9]), and volatile aliphatic and aromatic oximes attract parasitoids when released after herbivory by caterpillars ([@B49]; [@B56]; [@B52]). Moreover, volatile oximes are released as specific attractants for pollinators in moth-pollinated and night-blooming plants ([@B23]; [@B44]; [@B50]). Gaining knowledge about the function of the CYP79 enzymes provides molecular tools to engineer crop plants with new disease resistance properties ([@B5]).

In conclusion, characterization of CYP79 enzymes through pathway engineering in *N. benthamiana* is a powerful approach to assign biochemical function and substrate specificity to CYP79 enzymes, which is a prerequisite for understanding their functional role *in planta* and for using them as molecular tools in plant biotechnology to engineer glucosinolates and cyanogenic glucosides.
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